Your browser doesn't support javascript.
loading
Association of Plasma Vitamin D Metabolites With Incident Type 2 Diabetes: EPIC-InterAct Case-Cohort Study.
Zheng, Ju-Sheng; Imamura, Fumiaki; Sharp, Stephen J; van der Schouw, Yvonne T; Sluijs, Ivonne; Gundersen, Thomas E; Ardanaz, Eva; Boeing, Heiner; Bonet, Catalina; Gómez, Jesus Humberto; Dow, Courtney; Fagherazzi, Guy; Franks, Paul W; Jenab, Mazda; Kühn, Tilman; Kaaks, Rudolf; Key, Timothy J; Khaw, Kay-Tee; Lasheras, Cristina; Mokoroa, Olatz; Mancini, Francesca Romana; Nilsson, Peter M; Overvad, Kim; Panico, Salvatore; Palli, Domenico; Rolandsson, Olov; Sieri, Sabina; Salamanca-Fernández, Elena; Sacerdote, Carlotta; Spijkerman, Annemieke M W; Stepien, Magdalena; Tjonneland, Anne; Tumino, Rosario; Butterworth, Adam S; Riboli, Elio; Danesh, John; Langenberg, Claudia; Forouhi, Nita G; Wareham, Nicholas J.
Afiliação
  • Zheng JS; Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom.
  • Imamura F; Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom.
  • Sharp SJ; Medical Research Council Epidemiology Unit, University of Cambridge, Cambridge, United Kingdom.
  • van der Schouw YT; University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
  • Sluijs I; University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands.
  • Gundersen TE; Vitas AS, Oslo, Norway.
  • Ardanaz E; Navarra Public Health Institute, Pamplona, Spain.
  • Boeing H; Navarra Institute for Health Research, Pamplona, Spain.
  • Bonet C; Biomedical Research Center Network of Epidemiology and Public Health, Madrid, Spain.
  • Gómez JH; Department of Epidemiology, German Institute of Human Nutrition Potsdam-Rehbruecke, Nuthetal, Germany.
  • Dow C; Catalan Institute of Oncology-Bellvitge Biomedical Research Institute, Barcelona, Spain.
  • Fagherazzi G; Department of Epidemiology, Murcia Regional Health Council, IMIB-Arrixaca, Murcia, Spain.
  • Franks PW; Center for Research in Epidemiology and Population Health, Faculty of Medicine - University Paris-South, Faculty of Medicine INSERM U1018, University Paris-Saclay, Villejuif, France.
  • Jenab M; Gustave Roussy, Université Paris-Sud, Université Paris-Saclay, Villejuif, France.
  • Kühn T; Center for Research in Epidemiology and Population Health, Faculty of Medicine - University Paris-South, Faculty of Medicine INSERM U1018, University Paris-Saclay, Villejuif, France.
  • Kaaks R; Gustave Roussy, Université Paris-Sud, Université Paris-Saclay, Villejuif, France.
  • Key TJ; Department of Clinical Sciences, Lund University, Malmö, Sweden.
  • Khaw KT; International Agency for Research on Cancer, Lyon, France.
  • Lasheras C; Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
  • Mokoroa O; Division of Cancer Epidemiology, German Cancer Research Center, Heidelberg, Germany.
  • Mancini FR; University of Oxford, Oxford, United Kingdom.
  • Nilsson PM; Department of Public Health and Primary Care, University of Cambridge, Cambridge, United Kingdom.
  • Overvad K; Department of Functional Biology, Faculty of Medicine, University of Oviedo, Oviedo, Spain.
  • Panico S; Biomedical Research Center Network of Epidemiology and Public Health, Madrid, Spain.
  • Palli D; Public Health Division of Gipuzkoa, BioDonostia Research Institute, San Sebastian, Spain.
  • Rolandsson O; Center for Research in Epidemiology and Population Health, Faculty of Medicine - University Paris-South, Faculty of Medicine INSERM U1018, University Paris-Saclay, Villejuif, France.
  • Sieri S; Gustave Roussy, Université Paris-Sud, Université Paris-Saclay, Villejuif, France.
  • Salamanca-Fernández E; Department of Clinical Sciences, Lund University, Malmö, Sweden.
  • Sacerdote C; Department of Public Health, Section for Epidemiology, Aarhus University, Aarhus, Denmark.
  • Spijkerman AMW; Dipartimento di Medicina Clinica e Chirurgia, Federico II University, Naples, Italy.
  • Stepien M; Cancer Risk Factors and Life-Style Epidemiology Unit, Institute for Cancer Research, Prevention and Clinical Network, Florence, Italy.
  • Tjonneland A; Umeå University, Umeå, Sweden.
  • Tumino R; Epidemiology and Prevention Unit, Fondazione IRCSS Istituto Nazionale dei Tumori, Milan, Italy.
  • Butterworth AS; Biomedical Research Center Network of Epidemiology and Public Health, Madrid, Spain.
  • Riboli E; Escuela Andaluza de Salud Pública, Instituto de Investigación Biosanitaria ibs and Hospitales Universitarios de Granada/Universidad de Granada, Granada, Spain.
  • Danesh J; Unit of Cancer Epidemiology, Città della Salute e della Scienza Hospital-University of Turin and Center for Cancer Prevention, Torino, Italy.
  • Langenberg C; National Institute for Public Health and the Environment, Bilthoven, Netherlands.
  • Forouhi NG; International Agency for Research on Cancer, Lyon, France.
  • Wareham NJ; Danish Cancer Society Research Center, Copenhagen, Denmark.
J Clin Endocrinol Metab ; 104(4): 1293-1303, 2019 04 01.
Article em En | MEDLINE | ID: mdl-30418614
ABSTRACT

BACKGROUND:

Existing evidence for the prospective association of vitamin D status with type 2 diabetes (T2D) is focused almost exclusively on circulating total 25-hydroxyvitamin D [25(OH)D] without distinction between its subtypes nonepimeric and epimeric 25(OH)D3 stereoisomers, and 25(OH)D2, the minor component of 25(OH)D. We aimed to investigate the prospective associations of circulating levels of the sum and each of these three metabolites with incident T2D.

METHODS:

This analysis in the European Prospective Investigation into Cancer and Nutrition (EPIC)-InterAct case-cohort study for T2D included 9671 incident T2D cases and 13,562 subcohort members. Plasma vitamin D metabolites were quantified by liquid chromatography-mass spectrometry. We used a multivariable Prentice-weighted Cox regression to estimate hazard ratios (HRs) of T2D for each metabolite. Analyses were performed separately within country, and estimates were combined across countries using random-effects meta-analysis.

RESULTS:

The mean concentrations (SD) of total 25(OH)D, nonepimeric 25(OH)D3, epimeric 25(OH)D3, and 25(OH)D2 were 41.1 (17.2), 40.7 (17.3), 2.13 (1.31), and 8.16 (6.52) nmol/L, respectively. Plasma total 25(OH)D and nonepimeric 25(OH)D3 were inversely associated with incident T2D [multivariable-adjusted HR per 1 SD = 0.81 (95% CI, 0.77, 0.86) for both variables], whereas epimeric 25(OH)D3 was positively associated [per 1 SD HR = 1.16 (1.09, 1.25)]. There was no statistically significant association with T2D for 25(OH)D2 [per 1 SD HR = 0.94 (0.76, 1.18)].

CONCLUSIONS:

Plasma nonepimeric 25(OH)D3 was inversely associated with incident T2D, consistent with it being the major metabolite contributing to total 25(OH)D. The positive association of the epimeric form of 25(OH)D3 with incident T2D provides novel information to assess the biological relevance of vitamin D epimerization and vitamin D subtypes in diabetes etiology.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vitamina D / Diabetes Mellitus Tipo 2 Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Adult / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Vitamina D / Diabetes Mellitus Tipo 2 Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Adult / Female / Humans / Male / Middle aged País como assunto: Europa Idioma: En Ano de publicação: 2019 Tipo de documento: Article